Chicago-based Arch Venture Partners raised a $400 million fund to invest in early stage companies, the firm announced Wednesday, underscoring renewed investor confidence in the once moribund life sciences sector. Arch is best known for healthcare and biotech, with portfolio companies including Agios Pharmaceuticals Inc, Bluebird Bio and Receptos Inc. Those companies held initial public offerings last year and have since more than doubled their prices.
via Health News Headlines - Yahoo News http://ift.tt/1tVoJmq
via Health News Headlines - Yahoo News http://ift.tt/1tVoJmq
No comments:
Post a Comment